Breaking News, Collaborations & Alliances

Evotec Earns Boehringer Milestone

Oncology molecule moves into preclinical development

Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of €4 million to Evotec. The milestone was for the transition of an oncology molecule into preclinical development.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “This is the 20th milestone achieved as part of our alliance with Boehringer Ingelheim and represents a second oncology compound transitioning into preclinical development. I would like to congratulate the teams from both companies on their continuing excellent progress in the collaboration.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters